PTCB Quiz Prep

Medication Error Reporting Practice Questions

Updated · aligned to the 2026 PTCE outline

What gets reported, to whom, and where the technician's authority stops and the pharmacist's begins.

17 questionsAnswers includedUntimedEvery answer cited100% free

Key takeaways

  • FDA MedWatch takes adverse events and product problems. ISMP MERP takes medication errors and near misses.
  • A near miss is caught before reaching the patient, and it still gets reported.
  • Error reporting is non-punitive by design: blame suppresses reports, and suppressed reports hide system faults.
  • Anything requiring clinical judgment or patient counseling goes to the pharmacist.

Reporting questions test judgment more than recall. The exam wants to know whether you can tell a near miss from an error that reached the patient, which external program receives which report, and at what point a situation stops being yours to handle.

The escalation questions in this set are the ones candidates most often get wrong, because the correct answer is usually to involve the pharmacist rather than to act.

Want the same material as a timed, randomized run instead? Try the timed Patient Safety quiz and the Patient Safety & Quality Assurance domain guide.

All 17 error reporting questions and answers

Each answer is followed by an explanation and a link to the primary source it was checked against.

  1. 1. What is MedWatch?

    • A.A DEA database that tracks controlled substance prescriptions
    • B.The Joint Commission's sentinel event tracking system
    • C.A CDC program dedicated to reporting vaccine adverse events
    • D.The FDA's safety information and adverse event reporting program for medical products

    Answer: D. The FDA's safety information and adverse event reporting program for medical products

    MedWatch is the FDA's medical product safety reporting program for health professionals, patients, and consumers. It receives reports on products such as prescription and OTC medicines, biologics, devices, and combination products, and publishes safety alerts when appropriate. Vaccine events are handled by a separate system, VAERS.

    Source: fda.gov

  2. 2. A patient experiences a serious reaction after receiving a flu vaccination at the pharmacy. To which reporting system should this event be submitted?

    • A.VAERS, the Vaccine Adverse Event Reporting System
    • B.MedWatch, using voluntary Form FDA 3500
    • C.The ISMP National Medication Errors Reporting Program only
    • D.The DEA diversion reporting portal

    Answer: A. VAERS, the Vaccine Adverse Event Reporting System

    FDA guidance directs that vaccine adverse events be reported to VAERS rather than through MedWatch. VAERS is the national vaccine safety surveillance system. MedWatch covers drugs, biologics, devices, combination products, and similar FDA-regulated products, and the DEA portal deals with diversion, not adverse events.

    Source: fda.gov

  3. 3. Which MedWatch form is specifically designed for voluntary reporting by consumers and patients?

    • A.Form FDA 3500A
    • B.Form FDA 3500B
    • C.Form FDA 3500
    • D.DEA Form 222

    Answer: B. Form FDA 3500B

    Form FDA 3500B is the consumer- and patient-friendly version of the voluntary MedWatch reporting form, also available in Spanish. Form 3500 is the voluntary form for health professionals, while Form 3500A is reserved for mandatory reporting. DEA Form 222 is for ordering Schedule I and II controlled substances, not safety reporting.

    Source: fda.gov

  4. 4. Which statement about the ISMP National Medication Errors Reporting Program (ISMP MERP) is correct?

    • A.Reports must be filed by the pharmacy's corporate legal department
    • B.It accepts only errors that actually reached and harmed a patient
    • C.It is a confidential national program through which healthcare practitioners voluntarily report actual and potential medication errors
    • D.Reporter identities are published alongside every report

    Answer: C. It is a confidential national program through which healthcare practitioners voluntarily report actual and potential medication errors

    MERP is an internationally recognized program where healthcare professionals share potential or actual medication errors and hazardous conditions confidentially. ISMP staff follow up with reporters to clarify causes and contributing factors. ISMP guarantees confidentiality and respects the reporter's wishes about the detail included in publications.

    Source: home.ecri.org

  5. 5. A technician mistypes a dose during order entry, but the pharmacist catches it at verification and no incorrect label or product ever reaches the patient. How should this event be classified and handled?

    • A.As a near miss that should still be documented through the pharmacy's event reporting process
    • B.As a sentinel event requiring immediate state board notification
    • C.As a dispensing error that must be reported to MedWatch within 24 hours
    • D.As a non-event that requires no documentation

    Answer: A. As a near miss that should still be documented through the pharmacy's event reporting process

    The PTCE content outline lists near miss reporting alongside medication errors, root-cause analysis, and continuous quality improvement in its event reporting procedures. Near misses are intercepted before reaching the patient, but documenting them exposes the system weaknesses that allowed the error to start. No patient harm occurred, so it is not a sentinel event and MedWatch does not apply.

    Source: ptcb.org

  6. 6. A technician notices that two different products in the pharmacy have nearly identical caps and label colors and wants to warn the wider profession before an error happens anywhere. Which national program accepts confidential hazard reports of this kind from practitioners?

    • A.The DEA ARCOS reporting system
    • B.The state prescription drug monitoring program (PDMP)
    • C.CMS Open Payments
    • D.The ISMP National Medication Errors Reporting Program (ISMP MERP)

    Answer: D. The ISMP National Medication Errors Reporting Program (ISMP MERP)

    MERP accepts reports of hazardous conditions and potential errors, not just errors that already occurred. ISMP investigates reports, publishes lessons through its newsletters, and works with regulators and manufacturers, including the FDA, to fix packaging and labeling hazards. ARCOS, PDMPs, and Open Payments serve entirely different purposes.

    Source: home.ecri.org

  7. 7. After ECRI/ISMP receives a medication error report through MERP, what does the program do with the information?

    • A.It issues fines against the pharmacy where the error occurred
    • B.It forwards the reporter's name to the state board for discipline
    • C.It investigates the causes, shares learning through newsletters, and works with regulators and manufacturers to drive safety improvements
    • D.It automatically triggers a Class I recall of the product involved

    Answer: C. It investigates the causes, shares learning through newsletters, and works with regulators and manufacturers to drive safety improvements

    The MERP workflow is report, investigate, inform, and prevent: ISMP performs a comprehensive investigation, publicizes findings through newsletters and journals, and collaborates with partners such as the FDA and NCC MERP. ISMP is not an enforcement body, so it cannot fine pharmacies, discipline reporters, or order recalls. Reports remain confidential.

    Source: home.ecri.org

  8. 8. Following a serious dispensing error, a pharmacy team maps every step of its workflow to identify the underlying system failures that allowed the mistake to happen. Which quality process does this describe?

    • A.Therapeutic interchange
    • B.Root-cause analysis (RCA)
    • C.Prospective drug utilization review
    • D.Reverse distribution

    Answer: B. Root-cause analysis (RCA)

    Root-cause analysis is the retrospective process of digging past the individual mistake to the system-level causes, such as workflow, staffing, labeling, or technology gaps. The PTCE content outline lists RCA and continuous quality improvement under event reporting procedures. The other options relate to formulary substitution, order screening, and returning outdated stock.

    Source: ptcb.org

  9. 9. Which of the following would NOT be reported through the FDA MedWatch program?

    • A.A serious side effect from an over-the-counter pain reliever
    • B.A malfunctioning home glucose test kit
    • C.A reaction to a prefilled epinephrine auto-injector
    • D.An adverse reaction to a routine childhood vaccine

    Answer: D. An adverse reaction to a routine childhood vaccine

    MedWatch covers prescription and OTC medicines, biologics, medical devices such as glucose test kits, combination products such as prefilled auto-injectors, cannabinoid hemp products, and cosmetics. Vaccines follow a different pathway and should be reported to VAERS. FDA notes that vaccine reports sent to MedWatch are redirected, but direct VAERS submission is recommended.

    Source: fda.gov

  10. 10. Form FDA 3500A differs from Form FDA 3500 because Form 3500A is used for which purpose?

    • A.Mandatory adverse event reporting by manufacturers, user facilities, and IND researchers
    • B.Voluntary reporting by community pharmacists
    • C.Consumer-friendly voluntary reporting in Spanish
    • D.Reporting problems with tobacco and vaping products

    Answer: A. Mandatory adverse event reporting by manufacturers, user facilities, and IND researchers

    Form 3500A is the mandatory reporting form, used by industry, user facility personnel, and Investigational New Drug researchers when electronic submission is not required. Form 3500 is the voluntary form for health professionals, and 3500B serves consumers, including a Spanish version. Tobacco product problems go to the separate Safety Reporting Portal.

    Source: fda.gov

  11. 11. On the PTCE content outline effective January 2026, the Patient Safety and Quality Assurance domain accounts for what percentage of the exam?

    • A.23.75%
    • B.35%
    • C.18.75%
    • D.22.50%

    Answer: A. 23.75%

    Patient Safety and Quality Assurance is weighted at 23.75 percent of the PTCE. The other domains are Medications at 35 percent, Federal Requirements at 18.75 percent, and Order Entry and Processing at 22.50 percent. The safety domain covers high-alert and LASA drugs, error prevention, pharmacist intervention issues, event reporting, error types, and infection prevention.

    Source: ptcb.org

  12. 12. According to the PTCE content outline, which of the following is listed as an issue that requires pharmacist intervention?

    • A.Counting tablets for an already verified prescription
    • B.Printing a label for a routine refill
    • C.Making an over-the-counter product recommendation
    • D.Restocking the vitamin aisle

    Answer: C. Making an over-the-counter product recommendation

    PTCE knowledge area 3.3 lists issues requiring pharmacist intervention, including drug utilization review, adverse drug events, OTC recommendations, therapeutic substitution, misuse, adherence, post-immunization care, allergies, and drug interactions. Recommending an OTC product is clinical advice reserved for the pharmacist. Counting, labeling, and restocking are routine technician duties.

    Source: ptcb.org

  13. 13. A patient taking warfarin asks the technician which over-the-counter pain reliever is safe to use. What is the correct action?

    • A.Recommend ibuprofen, since it is sold without a prescription
    • B.Refer the patient to the pharmacist, because OTC recommendations and drug interactions require pharmacist intervention
    • C.Advise low-dose aspirin because many cardiac patients take it
    • D.Tell the patient any OTC pain product is fine when taken with food

    Answer: B. Refer the patient to the pharmacist, because OTC recommendations and drug interactions require pharmacist intervention

    This request combines two pharmacist-intervention triggers from the PTCE outline: an OTC recommendation and a potential drug interaction. NSAIDs and aspirin can significantly increase bleeding risk with warfarin, a clinical judgment the pharmacist must make. Technicians must recognize the situation and hand it off rather than advise.

    Source: ptcb.org

  14. 14. While a technician enters a new prescription, the pharmacy system displays a serious drug-drug interaction alert. What must the technician do?

    • A.Pass the alert to the pharmacist for clinical review rather than bypassing it
    • B.Override the alert if the patient has filled both drugs before
    • C.Cancel the prescription and contact the prescriber directly
    • D.Lower the entered dose until the alert no longer appears

    Answer: A. Pass the alert to the pharmacist for clinical review rather than bypassing it

    Drug utilization review findings and drug interactions are pharmacist-intervention issues under PTCE area 3.3. Resolving an interaction alert requires clinical judgment about risks, alternatives, and monitoring, which is outside the technician's role. Overriding alerts without review is a well-documented path to patient harm.

    Source: ptcb.org

  15. 15. At pickup, a patient mentions that the blood pressure medication started last week has been causing tongue swelling and trouble breathing at night. Beyond urging immediate medical attention for active symptoms, what should the technician do in the pharmacy?

    • A.Note the comment in the patient profile and finish ringing up the sale
    • B.Suggest an over-the-counter antihistamine to control the swelling
    • C.Tell the patient to stop the medication without involving the pharmacist
    • D.Alert the pharmacist right away, because a suspected adverse drug event requires pharmacist intervention

    Answer: D. Alert the pharmacist right away, because a suspected adverse drug event requires pharmacist intervention

    Tongue swelling and breathing difficulty suggest angioedema, a serious adverse drug event, and ADEs are listed in PTCE area 3.3 as requiring pharmacist intervention. The pharmacist evaluates the reaction, contacts the prescriber, and may submit a MedWatch report to FDA. A technician recommending an OTC product or advising discontinuation would be practicing outside their role.

    Source: ptcb.org

  16. 16. A prescription for amoxicillin arrives for a patient whose profile documents a penicillin allergy, and an allergy alert fires during order entry. Which response is correct for the technician?

    • A.Delete the allergy from the profile since the prescriber must know best
    • B.Stop and escalate the allergy alert to the pharmacist before any further processing
    • C.Dispense the drug with an auxiliary allergy warning label
    • D.Automatically switch the order to a different antibiotic

    Answer: B. Stop and escalate the allergy alert to the pharmacist before any further processing

    Allergies are explicitly listed among the pharmacist-intervention issues in PTCE area 3.3. Amoxicillin is a penicillin, so this alert flags a potentially dangerous cross-reaction that only the pharmacist can assess, often by contacting the prescriber. Technicians never delete allergy records, bypass alerts, or make therapeutic substitutions on their own.

    Source: ptcb.org

  17. 17. A patient tries to refill an oxycodone prescription ten days early for the third month in a row, saying the tablets keep running out. Under the PTCE outline's pharmacist-intervention areas, why must the technician involve the pharmacist?

    • A.Early refills always require a new DEA Form 222 from the prescriber
    • B.Only pharmacists are permitted to operate the register for controlled substances
    • C.Suspected misuse and adherence concerns are issues that require pharmacist intervention
    • D.Insurance early-refill rejections can only be overridden by a pharmacist

    Answer: C. Suspected misuse and adherence concerns are issues that require pharmacist intervention

    A repeated pattern of early opioid refills raises misuse and adherence concerns, both named in PTCE area 3.3 as requiring pharmacist intervention. The pharmacist exercises corresponding responsibility in deciding whether the prescription is legitimate and whether to contact the prescriber. DEA Form 222 governs Schedule I and II ordering between registrants, not patient refills.

    Source: ptcb.org

Error Reporting: FAQ

What is the difference between MedWatch and ISMP MERP?

MedWatch is the FDA's program for reporting adverse events, side effects and product quality problems. ISMP's Medication Errors Reporting Program collects medication errors and near misses, including the circumstances around them, and feeds the findings back into practice recommendations.

Should a near miss be reported?

Yes. A near miss is an error caught before it reached the patient, and it reveals the same system weakness a real error would have. Reporting it is how the weakness gets fixed before someone is harmed.

When must a pharmacy technician escalate to the pharmacist?

Any time the situation calls for clinical judgment: a patient question about their therapy, a drug interaction alert, a suspected error, a prescription that looks altered, or a request for counseling. Technicians handle the technical and workflow side; interpretation belongs to the pharmacist.

Official sources checked

Every answer above was written against a primary source and verified independently. These are the 4 sources behind this set.

More practice question sets

Sig CodesHigh-Alert MedicationsLASA DrugsDrug InteractionsStorage & ExpirationBilling & InsuranceControlled Substances

Prefer a timed run? Browse every free PTCB practice test.

PTCB Quiz Prep is an independent study resource and is not affiliated with the Pharmacy Technician Certification Board.